[Current view on the issue of insufficient effectiveness of anti-VEGF therapy for age-related macular degeneration].

Due to the significant medical and social importance of neovascular (wet) age-related macular degeneration (wAMD), increasing the effectiveness of anti-VEGF therapy used to treat this disease is one of the high-priority problems in modern retinology. This article focuses on pathobiological aspects and clinical manifestations of incomplete responses to anti-VEGF therapy of wAMD, considers the proposed ways to improve the terminology and classification of responses to therapy, as well as the assessment of its correctness and effectiveness of the treatment. It also discusses the available ways to optimize anti-VEGF therapy and define the criteria of its termination in cases when the treatment proves to be futile.

[Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response].

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of decreased vision in the elderly population in many countries, including Russia. Anti-VEGF therapy is undoubtedly the «gold standard» of treatment for the disease, but its use in different patients is known to produce results with significant interindividual differences. This article reviews modern ideas about the clinical assessment of the degree of response to anti-VEGF therapy, possible reasons for its insufficient effectiveness (clinical, pharmacological, or related to nAMD pathogenesis), discusses the potential applications of the existing therapeutic strategies, and considers the prospects for the emergence of new strategies that could be used for solving that problem.

[Anti-VEGF therapy of wet age-related macular degeneration: analysis of patients lost to follow-up].

Unlabelled: Patients lost to follow-up (LTFU) are a well-recognized challenge, both in clinical trials and in real clinical practice.

Purpose: To study the reasons for patients receiving anti-VEGF therapy for «wet» age-related macular degeneration (wAMD) in clinical environment to cease monitoring in the clinic.

Material And Methods: This retrospective cohort study included patients with wAMD which received anti-VEGF therapy (ranibizumab, aflibercept) in the Ural State Medical University clinic from 2011 to 2019 (=241).

[Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organasation «Association of Ophthalmologists»].

Intravitreal drug administration is a procedure that has become widespread in modern ophthalmology. However, there is no global consensus on certain aspects of this manipulation, and practitioners feel the need for guidelines. In the Russian Federation, until now, such a document was not available.

[Long-term outcomes of anti-angiogenic therapy for macular neovascular disorders].

Aim: to study long-term (≥2-year) RESULTS of ranibizumab treatment in patients with macular neovascular disorders.

Material And Methods: The study group included 27 patients (mean age±SD of 66.7±13.